Elliot Wilbur
Stock Analyst at Raymond James
(1.57)
# 2,458
Out of 4,667 analysts
54
Total ratings
31.11%
Success rate
-2.56%
Average return
Main Sectors:
Stocks Rated by Elliot Wilbur
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADMA ADMA Biologics | Maintains: Strong Buy | $18 → $25 | $20.63 | +21.18% | 7 | Nov 8, 2024 | |
| ANIP ANI Pharmaceuticals | Maintains: Outperform | $81 → $83 | $55.69 | +49.04% | 12 | Sep 18, 2024 | |
| SLGL Sol-Gel Technologies | Downgrades: Outperform | $6 → $4 | $0.43 | +828.07% | 8 | Aug 19, 2024 | |
| OGN Organon & Co. | Initiates: Outperform | $33 | $14.59 | +126.18% | 1 | Mar 16, 2023 | |
| PRGO Perrigo Company | Maintains: Outperform | $42 → $43 | $27.24 | +57.86% | 6 | Mar 6, 2023 | |
| PYPD PolyPid | Downgrades: Outperform | $450 → $120 | $3.60 | +3,233.33% | 3 | Sep 6, 2022 | |
| VTRS Viatris | Downgrades: Market Perform | n/a | $13.05 | - | 3 | Mar 1, 2022 | |
| TEVA Teva Pharmaceutical | Downgrades: Market Perform | n/a | $16.81 | - | 4 | Oct 28, 2021 | |
| ZTS Zoetis | Downgrades: Market Perform | n/a | $175.56 | - | 4 | Jul 16, 2021 | |
| ELAN Elanco Animal Health | Initiates: Market Perform | n/a | $13.31 | - | 1 | Jan 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $5.35 | - | 2 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $43.62 | - | 3 | Nov 9, 2017 |
ADMA Biologics
Nov 8, 2024
Maintains: Strong Buy
Price Target: $18 → $25
Current: $20.63
Upside: +21.18%
ANI Pharmaceuticals
Sep 18, 2024
Maintains: Outperform
Price Target: $81 → $83
Current: $55.69
Upside: +49.04%
Sol-Gel Technologies
Aug 19, 2024
Downgrades: Outperform
Price Target: $6 → $4
Current: $0.43
Upside: +828.07%
Organon & Co.
Mar 16, 2023
Initiates: Outperform
Price Target: $33
Current: $14.59
Upside: +126.18%
Perrigo Company
Mar 6, 2023
Maintains: Outperform
Price Target: $42 → $43
Current: $27.24
Upside: +57.86%
PolyPid
Sep 6, 2022
Downgrades: Outperform
Price Target: $450 → $120
Current: $3.60
Upside: +3,233.33%
Viatris
Mar 1, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $13.05
Upside: -
Teva Pharmaceutical
Oct 28, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $16.81
Upside: -
Zoetis
Jul 16, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $175.56
Upside: -
Elanco Animal Health
Jan 10, 2020
Initiates: Market Perform
Price Target: n/a
Current: $13.31
Upside: -
Jan 17, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $5.35
Upside: -
Nov 9, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $43.62
Upside: -